As part of its response to the Covid-19 pandemic, EUnetHTA is working to output ‘Rolling Collaborative Reviews (RCR)’. The objective of such reviews is to provide decision-makers with a timely synthesis of available evidence on the comparative effectiveness of therapeutic health technologies relevant to the management of the current pandemic.
EUnetHTA is pleased to announce that the second round of these monthly updated Covid-19 Rolling Collaborative Reviews (RCR) is now available.
Please access the reviews, together with the project description and planning, here:
RCR01-RCRXX – Project Description and Planning
RCR01: Convalescent Plasma Treatment
RCR02: Lopinavir + Ritonavir (Kaletra©)
RCR03: Tocilizumab (RoActemra©)